In today’s recent session, 0.68 million shares of the CRISPR Therapeutics AG (NASDAQ:CRSP) have been traded, and its beta is 1.94. Most recently the company’s share price was $81.54, and it changed around $5.2 or 6.81% from the last close, which brings the market valuation of the company to $6.22B. CRSP at last check was trading at a discount to its 52-week high of $142.64, offering almost -74.93% off that amount. The share price’s 52-week low was $42.51, which indicates that the recent value has risen by an impressive 47.87% since then. We note from CRISPR Therapeutics AG’s average daily trading volume that its 10-day average is 1.26 million shares, with the 3-month average coming to 1.99 million.
CRISPR Therapeutics AG stock received a consensus recommendation rating of an Overweight, based on a mean score of 2.20. If we narrow it down even further, the data shows that 1 out of 27 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 9 recommended CRSP as a Hold, whereas 16 deemed it a Buy, and 0 rated it as Underweight. CRISPR Therapeutics AG is expected to report earnings per share of -$2.23 for the current quarter.
CRISPR Therapeutics AG (NASDAQ:CRSP) trade information
Instantly CRSP has been showing a green trend so far today with a performance of 6.81% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 83.01 on Tuesday, 08/02/22 increased the stock’s daily price by 1.77%. The company’s shares are currently up 0.74% year-to-date, but still down -1.01% over the last five days. On the other hand, CRISPR Therapeutics AG (NASDAQ:CRSP) is 19.67% down in the 30-day period. We can see from the shorts that 11.53 million shares have been sold at a short interest cover period of 3.91 day(s).
The consensus price target as assigned by Wall Street analysts is $113.77, which translates to bulls needing to increase their stock price by 28.33% from its current value. Analyst projections state that CRSP is forecast to be at a low of $46.00 and a high of $220.00. In order for the stock price to hit the forecast high, the stock would need to plunge -169.81% from its current level, while the stock would need to crash 43.59% from its current level to reach the projected low.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
CRISPR Therapeutics AG share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 19.75 percent over the past six months and at a -291.06% annual growth rate that is well below the industry average of 1.00%. Moreover, analysts have decided to roll up on their fiscal year 2022 revenue estimates. The rating firms predict that it will loss -123.60% in revenue this quarter, and will report a decrease of -35.90% in the next quarter. The year-over-year growth rate is expected to be -98.90%, down from the previous year.
Consensus estimates provided by 15 financial analysts predict the company will bring in an average of $2.06 million in revenue for the current quarter. 15 analysts expect CRISPR Therapeutics AG to make $2.07 million in revenue for the quarter ending Sep 2022. Forecasts for the next quarter put sales growth at 84.80%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 35.00%.
CRISPR Therapeutics AG’s next quarterly earnings report is expected to be released around April 25 and April 29.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.33% of CRISPR Therapeutics AG shares, and 63.93% of them are in the hands of institutional investors. The stock currently has a share float of 64.80%. CRISPR Therapeutics AG stock is held by 576 institutions, with ARK Investment Management, LLC being the largest institutional investor. By Jun 29, 2022, it held 12.56% of the shares, which is about 9.73 million shares worth $591.14 million.
Nikko Asset Management Americas, Inc., with 5.96% or 4.62 million shares worth $289.98 million as of Mar 30, 2022, holds the second largest percentage of outstanding shares.
ARK ETF Tr-ARK Innovation ETF and New Perspective Fund Inc were the top two Mutual Funds as of Jun 29, 2022. The former held 6.78 million shares worth $412.28 million, making up 8.76% of all outstanding shares. On the other hand, New Perspective Fund Inc held roughly 2.16 million shares worth around $131.38 million, which represents about 2.79% of the total shares outstanding.